

K984501

JUL 28 1999

**510(k) Summary  
For Dade Behring BFTII**

**1. Manufactures Name, Address, Telephone, and Contact Person, Date of Preparation:**

Manufacturer: Dade Behring Marburg GmbH  
Emil-von-Behring Str. 76  
Marburg/Germany

Contact Information: Dade Behring Inc.  
Glasgow Site  
P.O. Box 6101  
Newark, Delaware 19714  
Attn: Rebecca S. Ayash  
Tel: 302-631-6276

Preparation date: June 29, 1999

**2. Device Name/ Classification:**

Dade Behring Fibrintimer II (BFTII): Multipurpose system for *in vitro* coagulation studies  
Classification Number: Class II (864.5425)

**3. Identification of the Legally Marketed Device:**

Behring Coagulation Timer & CA-6000

**4. Device Description:**

Dade Behring BFTII is a semi-automated opto-mechanical coagulation analyzer. The BFTII is used in conjunction with coagulation reagents for measurement of various coagulometric tests.

**5. Device Intended Use:**

The Dade Behring Fibrintimer II (BFTII) is a semi-automated device intended for use to determine PT, aPTT, and Fibrinogen.

**6. Medical device to which equivalence is claimed and comparison information:**

There are a number of multipurpose systems for *in vitro* coagulation studies. Two such products are the Dade Behring BCT, K955278 and CA-6000, K964139. The BFTII is substantially equivalent in intended use and results obtained to both the BCT and CA-6000. The BFTII, like the BCT and CA-6000, performs quantitative measurement of coagulometric tests by optical clot detection.

000019



DEPARTMENT OF HEALTH & HUMAN SERVICES

Food and Drug Administration  
2098 Gaither Road  
Rockville MD 20850

JUL 28 1999

Ms. Rebecca S. Ayash  
Manager, Regulatory and Biology  
Dade Behring, Inc.  
Glasgow Building 500, Mailbox 514  
P.O. Box 6101  
Newark, Delaware 19714-6101

Re: K984501  
Trade Name: Dade Behring BFTII  
Regulatory Class: II  
Product Code: JPA  
Dated: May 12, 1998  
Received: May 13, 1998

Dear Ms. Ayash:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895.

A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.


Page 2

Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at (770) 488-7655.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597, or at its internet address "<http://www.fda.gov/cdrh/dsma/dsmamain.html>".

Sincerely yours,

A handwritten signature in black ink that reads "Steven Gutman". The signature is written in a cursive, flowing style.

Steven I. Gutman, M.D, M.B.A.  
Director  
Division of Clinical  
Laboratory Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health


Enclosure

## Indications Statement

Device Name: Dade Behring BFTII

### Indications for Use:

The Dade Behring BFTII is a semi-automated device intended for use to determine PT, aPTT, and Fibrinogen.

  
(Director of) \_\_\_\_\_  
Director of Regulatory Devices 2984501  
510(k) Number \_\_\_\_\_

(PLEASE DO NOT WRITE BELOW THIS LINE – CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use ☒  
(Per 21 CFR 801.109)

Over-The-Counter-Use \_\_\_\_\_  
(Optional Format 1-2-96)